Literature DB >> 21827813

RSV 2010: Recent advances in research on respiratory syncytial virus and other pneumoviruses.

Grada M van Bleek1, Albert D M E Osterhaus, Rik L de Swart.   

Abstract

Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) are important causes of acute respiratory tract disease in infants, immunocompromised patients and the elderly. The Seventh International RSV symposium was held in Rotterdam, the Netherlands, from December 2-5, 2010. This symposium is the flagship event for leading investigators engaged in RSV and HMPV research around the world. The objective of the symposium was to provide a forum to review recent advances in research on RSV, HMPV and other pneumoviruses. More than 200 young and established investigators attended the meeting. Over a hundred papers were presented in 55 oral presentations and six poster sessions, providing all participants the opportunity to share and to discuss their work. The Chanock lecture, instituted in 2003 to acknowledge important contributors to RSV research, was presented by Peter Collins. As a preface to his lecture, he presented an in memoriam of the late Dr. Robert M. Chanock, who played a key role in the characterization of RSV as a human pathogen. The current report presents highlights of the meeting, covering topics from basic virology, pathogenesis and immunology to clinical studies, therapeutics and vaccine development.
Copyright © 2011. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21827813     DOI: 10.1016/j.vaccine.2011.07.114

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Burden of respiratory syncytial virus infection in young children.

Authors:  Bernhard Resch
Journal:  World J Clin Pediatr       Date:  2012-10-08

2.  Impaired immune response to vaccination against infection with human respiratory syncytial virus at advanced age.

Authors:  Teun Guichelaar; Jeroen Hoeboer; Myra N Widjojoatmodjo; Sylvia S N Reemers; Cécile A C M van Els; Rob Otten; Yvonne van Remmerden; Jolande Boes; Willem Luytjes
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

3.  Depletion of alveolar macrophages prolongs survival in response to acute pneumovirus infection.

Authors:  Peter Rigaux; Kristin E Killoran; Zhijun Qiu; Helene F Rosenberg
Journal:  Virology       Date:  2011-11-30       Impact factor: 3.616

4.  mRNA cap methylation influences pathogenesis of vesicular stomatitis virus in vivo.

Authors:  Yuanmei Ma; Yongwei Wei; Xiaodong Zhang; Yu Zhang; Hui Cai; Yang Zhu; Konstantin Shilo; Michael Oglesbee; Steven Krakowka; Sean P J Whelan; Jianrong Li
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

Review 5.  Inflammatory responses to respiratory syncytial virus (RSV) infection and the development of immunomodulatory pharmacotherapeutics.

Authors:  H F Rosenberg; J B Domachowske
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

6.  The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents.

Authors:  Thien N Nguyen; Ultan F Power; Alain Robert; Jean-François Haeuw; Katia Helffer; Amadeo Perez; Miguel-Angel Asin; Nathalie Corvaia; Christine Libon
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

Review 7.  Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials.

Authors:  Lindsay Broadbent; Helen Groves; Michael D Shields; Ultan F Power
Journal:  Influenza Other Respir Viruses       Date:  2015-07       Impact factor: 4.380

Review 8.  Respiratory syncytial virus entry inhibitors targeting the F protein.

Authors:  Zhiwu Sun; Yanbin Pan; Shibo Jiang; Lu Lu
Journal:  Viruses       Date:  2013-01-16       Impact factor: 5.048

Review 9.  Strategic priorities for respiratory syncytial virus (RSV) vaccine development.

Authors:  L J Anderson; P R Dormitzer; D J Nokes; R Rappuoli; A Roca; B S Graham
Journal:  Vaccine       Date:  2013-04-18       Impact factor: 3.641

Review 10.  Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.

Authors:  Arwen F Altenburg; Joost H C M Kreijtz; Rory D de Vries; Fei Song; Robert Fux; Guus F Rimmelzwaan; Gerd Sutter; Asisa Volz
Journal:  Viruses       Date:  2014-07-17       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.